Integrating heterogeneous data to facilitate COVID-19 drug repurposing

In the COVID-19 pandemic, drug repositioning has presented itself as an alternative to the time-consuming process of generating new drugs. This review describes a drug repurposing process that is based on a new data-driven approach: we put forward five information paths that associate COVID-19-relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Prieto Santamaría, Lucía, Díaz Uzquiano, Marina, Ugarte Carro, Esther, Ortiz-Roldán, Nieves, Pérez Gallardo, Yuliana, Rodríguez-González, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Post-Screen (Grey)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520166/
https://www.ncbi.nlm.nih.gov/pubmed/34666181
http://dx.doi.org/10.1016/j.drudis.2021.10.002
Descripción
Sumario:In the COVID-19 pandemic, drug repositioning has presented itself as an alternative to the time-consuming process of generating new drugs. This review describes a drug repurposing process that is based on a new data-driven approach: we put forward five information paths that associate COVID-19-related genes and COVID-19 symptoms with drugs that directly target these gene products, that target the symptoms or that treat diseases that are symptomatically or genetically similar to COVID-19. The intersection of the five information paths results in a list of 13 drugs that we suggest as potential candidates against COVID-19. In addition, we have found information in published studies and in clinical trials that support the therapeutic potential of the drugs in our final list.

Ejemplares similares